The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.
 
Shukui Qin
No Relationships to Disclose
 
Yuxian Bai
No Relationships to Disclose
 
Zishu Wang
No Relationships to Disclose
 
Zhendong Chen
No Relationships to Disclose
 
Ruihua Xu
No Relationships to Disclose
 
Jianming Xu
No Relationships to Disclose
 
Hongmei Zhang
No Relationships to Disclose
 
Jia Chen
No Relationships to Disclose
 
Ying Yuan
No Relationships to Disclose
 
Tianshu Liu
No Relationships to Disclose
 
Lin Yang
No Relationships to Disclose
 
Haijun Zhong
No Relationships to Disclose
 
Donghui Chen
No Relationships to Disclose
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squib; Daiichi Sankyo; Harbour BioMed; Merck; Mingji biopharmaceutical; MSD; Roche
Speakers' Bureau - Hutchison Whampoa; MSD
Research Funding - Baiji Shenzhou (Beijing) Biotechnology Co., Ltd (Inst); Beijing Xiantong Biomedical Technology Co., Ltd (Inst); Nanjing Yaojieankang Biotechnology (Inst); QiLu Pharmaceutical (Inst); Zaiding Pharmaceutical (Inst)
 
Chunyi Hao
No Relationships to Disclose
 
Deliang Fu
No Relationships to Disclose
 
Ying Cheng
No Relationships to Disclose
 
Jianwei Yang
No Relationships to Disclose
 
Xian hong Bai
No Relationships to Disclose
 
Jin Li
No Relationships to Disclose